Dundalk, Ireland, Feb. 27, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it was recently honored to receive the Grand Prix – FDI Company of the Year award and the Best Regional Investment award at the 2023 Invest in Ireland Awards.
The Invest in Ireland Awards recognize contributions that the foreign direct investment (FDI) sector makes to the Irish economy and society across various industries such as tech, pharma, green economy, business services and engineering. WuXi Biologics’ investments in building state-of-the-art manufacturing facilities in Ireland has resulted in significant direct employment growth, integration into the community, and spill-over economic effects. The company has hired more than 500 people – mainly from the local area and North-East region – for highly skilled and well-paid jobs, and created over 6,000 construction jobs. It has also developed a diverse and inclusive workplace culture, and has supported various local charities and community organizations, such as Breast Cancer Ireland and Pieta House.
Brendan McGrath, Vice President, Head of WuXi Biologics Ireland Site, commented, “We are grateful for the support of IDA Ireland, and local communities that have made our success possible. We are proud to be recognized as a successful FDI investor and look forward to continuing our contribution to local economic and social development. As our Ireland site progresses towards GMP manufacturing, we’re excited about seeing more of our clients’ innovative biologics being manufactured here for the global market.”
Dr. Chris Chen, CEO of WuXi Biologics, added, “Ireland site plays a strategically important role in our global network. The investment in Ireland reflects our commitment to enhancing our capability and expertise in line with customer needs. We will continue to enable global partners to discover, develop and manufacture biologics to benefit patients worldwide.”
The client engineering and PPQ batches at WuXi Biologics Ireland’s site are on track, with the first PPQ campaign is planned for both manufacturing suites in 2023. In December 2022 – only 9 months since the start of operations – the Ireland site received its first GMP certificate from the Health Products Regulatory Authority (HPRA), a notable demonstration of “WuXi Biologics Quality” and “WuXi Biologics Speed”.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com